NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|10505362|gb|AAG18447|]
View 

neprilysin-like peptidase beta [Mus musculus]

Protein Classification

M13 family metallopeptidase( domain architecture ID 10171382)

M13 family metallopeptidase similar to neutral endopeptidase (neprilysin), which degrades and inactivates bioactive peptides, and to endothelin-converting enzyme, which catalyzes the hydrolysis of the bond between Trp-21 and Val-22 in big endothelin to form endothelin 1

EC:  3.4.24.-
Gene Ontology:  GO:0008270|GO:0008237
MEROPS:  M13
PubMed:  18215274|7674922

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
96-763 0e+00

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


:

Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 787.33  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362  96 NPCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQH--RPAVEKAKTLYRSCMNQSVIEKRDSE 173
Cdd:cd08662   2 DPCDDFYQYACGNWLKNHPIPADKSSWGSFSELQDRNEEQLREILEEAASSAadSSAEQKAKDFYKSCMDEEAIEKLGLK 81
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 174 PLLSVLKMVGGWPVAMDKWNETmglkwelerqLAVLNSQFNRRVLIDLFIWNDDQNSSRHVIYIDQPTLGMPSREYYFQE 253
Cdd:cd08662  82 PLKPLLDKIGGLPSLDDLAAEL----------LLALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYLDE 151
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 254 DNNhKVRKAYLEFMTSVATMLRKDQNLSKEsamvreEMAEVLELETHLANATVPQEKRHDVTALYHRMDLMELQERFglK 333
Cdd:cd08662 152 ENA-EIREAYKKYIAKLLELLGADEEEAEK------LAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLA--P 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 334 GFNWTLFIQNVLSSVEvelfPDEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFKEARVDYRKALY 413
Cdd:cd08662 223 SIDWKAYLKALGPPAD----DPDKVIVSQPEYLKKLDKLLASTPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFYGKALS 298
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 414 GTTVEEVRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKKKAQEKAMNIREQ 493
Cdd:cd08662 299 GQKEPEPRWKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLDAMKVK 378
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 494 IGYPDYILedNNKHLDEEYSSLTFyEDLYFENGLQNLKNNAQRSLKKLREKVDQNLWIIGAAVVNAFYSPNRNQIVFPAG 573
Cdd:cd08662 379 IGYPDKWR--DYSALDIYYDDLNV-SDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIVFPAG 455
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 574 ILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSARHFQQQSQCMIYQYGNFswELADNQN 653
Cdd:cd08662 456 ILQPPFFDPDAPDALNYGGIGAVIGHEITHGFDDQGRQYDENGNLRNWWTNEDRKEFEERAQCLVDQYSNY--EVPPGLH 533
                       570       580       590       600       610       620       630       640
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 654 VNGFSTLGENIADNGGVRQAYKAYLRWLADGGKDQrLPGLNLTYAQLFFINYAQVWCGSYRPEFAVQSIKTDVHSPLKYR 733
Cdd:cd08662 534 VNGKLTLGENIADNGGLRLAYRAYKKWLKENGPEL-PGLEGFTPEQLFFLSFAQVWCSKYRPEALRQLLLTDPHSPGKFR 612
                       650       660       670
                ....*....|....*....|....*....|
gi 10505362 734 VLGSLQNLPGFSEAFHCPRGSPMHPMKRCR 763
Cdd:cd08662 613 VNGPLSNSPEFAEAFNCPPGSPMNPEKKCR 642
 
Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
96-763 0e+00

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 787.33  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362  96 NPCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQH--RPAVEKAKTLYRSCMNQSVIEKRDSE 173
Cdd:cd08662   2 DPCDDFYQYACGNWLKNHPIPADKSSWGSFSELQDRNEEQLREILEEAASSAadSSAEQKAKDFYKSCMDEEAIEKLGLK 81
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 174 PLLSVLKMVGGWPVAMDKWNETmglkwelerqLAVLNSQFNRRVLIDLFIWNDDQNSSRHVIYIDQPTLGMPSREYYFQE 253
Cdd:cd08662  82 PLKPLLDKIGGLPSLDDLAAEL----------LLALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYLDE 151
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 254 DNNhKVRKAYLEFMTSVATMLRKDQNLSKEsamvreEMAEVLELETHLANATVPQEKRHDVTALYHRMDLMELQERFglK 333
Cdd:cd08662 152 ENA-EIREAYKKYIAKLLELLGADEEEAEK------LAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLA--P 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 334 GFNWTLFIQNVLSSVEvelfPDEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFKEARVDYRKALY 413
Cdd:cd08662 223 SIDWKAYLKALGPPAD----DPDKVIVSQPEYLKKLDKLLASTPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFYGKALS 298
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 414 GTTVEEVRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKKKAQEKAMNIREQ 493
Cdd:cd08662 299 GQKEPEPRWKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLDAMKVK 378
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 494 IGYPDYILedNNKHLDEEYSSLTFyEDLYFENGLQNLKNNAQRSLKKLREKVDQNLWIIGAAVVNAFYSPNRNQIVFPAG 573
Cdd:cd08662 379 IGYPDKWR--DYSALDIYYDDLNV-SDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIVFPAG 455
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 574 ILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSARHFQQQSQCMIYQYGNFswELADNQN 653
Cdd:cd08662 456 ILQPPFFDPDAPDALNYGGIGAVIGHEITHGFDDQGRQYDENGNLRNWWTNEDRKEFEERAQCLVDQYSNY--EVPPGLH 533
                       570       580       590       600       610       620       630       640
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 654 VNGFSTLGENIADNGGVRQAYKAYLRWLADGGKDQrLPGLNLTYAQLFFINYAQVWCGSYRPEFAVQSIKTDVHSPLKYR 733
Cdd:cd08662 534 VNGKLTLGENIADNGGLRLAYRAYKKWLKENGPEL-PGLEGFTPEQLFFLSFAQVWCSKYRPEALRQLLLTDPHSPGKFR 612
                       650       660       670
                ....*....|....*....|....*....|
gi 10505362 734 VLGSLQNLPGFSEAFHCPRGSPMHPMKRCR 763
Cdd:cd08662 613 VNGPLSNSPEFAEAFNCPPGSPMNPEKKCR 642
PepO COG3590
Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];
88-765 0e+00

Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];


Pssm-ID: 442809 [Multi-domain]  Cd Length: 674  Bit Score: 620.63  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362  88 LENMDQSRNPCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQHRPA--VE-KAKTLYRSCMNQ 164
Cdd:COG3590  30 LANMDTSVRPGDDFYRYVNGGWLKTTPIPADRSRWGSFNELRERNEARLRAILEEAAAAPAAAgsDEqKIGDLYASFMDE 109
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 165 SVIEKRDSEPLLSVLKMVggwpvamdkwnETMGLKWELERQLAVLNSQFNRrVLIDLFIWNDDQNSSRHVIYIDQPTLGM 244
Cdd:COG3590 110 AAIEALGLAPLKPDLARI-----------DAIKDKADLAALLAALHRAGVG-GLFGFGVDADLKNSTRYIAYLGQGGLGL 177
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 245 PSREYYFQEDNNHK-VRKAYLEFmtsVATMLRkdqnLSKESAMVREEMAE-VLELETHLANATVPQEKRHDVTALYHRMD 322
Cdd:COG3590 178 PDRDYYLKDDEKSAeIRAAYVAH---VAKMLE----LAGYDEADAAAAAEaVLALETALAKAHWSRVELRDPEKTYNPMT 250
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 323 LMELQERFglKGFNWTLFiqnvLSSVEVELFpdEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFK 402
Cdd:COG3590 251 VAELAKLA--PGFDWDAY----LKALGLPAV--DEVIVGQPSFFKALDKLLASTPLEDWKAYLRWHLLDSAAPYLSKAFV 322
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 403 EARVD-YRKALYGTTVEEVRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKK 481
Cdd:COG3590 323 DANFDfYGKTLSGQKEQRPRWKRAVALVNGALGEALGQLYVERYFPPEAKARMEELVANLRAAYRERIENLDWMSPETKA 402
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 482 KAQEKAMNIREQIGYPDYilednnkhlDEEYSSLTFYEDLYFENGLQNLKNNAQRSLKKLREKVDQNLWIIGAAVVNAFY 561
Cdd:COG3590 403 KALEKLAAFTPKIGYPDK---------WRDYSGLEIKRDDLVGNVLRASAFEYQRELAKLGKPVDRTEWGMTPQTVNAYY 473
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 562 SPNRNQIVFPAGILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSARHFQQQSQCMIYQY 641
Cdd:COG3590 474 NPTMNEIVFPAAILQPPFFDPKADDAVNYGGIGAVIGHEITHGFDDQGSQFDGDGNLRNWWTPEDRAAFEARTKKLVAQY 553
                       570       580       590       600       610       620       630       640
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 642 GNFswELADNQNVNGFSTLGENIADNGGVRQAYKAYLRWLadggKDQRLPGLN-LTYAQLFFINYAQVWCGSYRPEFAVQ 720
Cdd:COG3590 554 DAY--EPLPGLHVNGKLTLGENIADLGGLSIAYDAYKLSL----KGKEAPVIDgFTGDQRFFLGWAQVWRSKARDEALRQ 627
                       650       660       670       680
                ....*....|....*....|....*....|....*....|....*..
gi 10505362 721 SIKTDVHSPLKYRVLGSLQNLPGFSEAFHCPRGSPMH--PMKRCRIW 765
Cdd:COG3590 628 RLATDPHSPGEFRVNGPVRNLDAFYEAFDVKPGDKMYlaPEDRVRIW 674
Peptidase_M13_N pfam05649
Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of ...
97-497 4.32e-149

Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of organizms including mammals and bacteria. In mammals they participate in processes such as cardiovascular development, blood-pressure regulation, nervous control of respiration, and regulation of the function of neuropeptides in the central nervous system. In bacteria they may be used for digestion of milk.


Pssm-ID: 461703  Cd Length: 382  Bit Score: 440.58  E-value: 4.32e-149
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362    97 PCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQH--RPAVEKAKTLYRSCMNQSVIEKRDSEP 174
Cdd:pfam05649   1 PCDDFYQYACGGWLKNHPIPADKSSWGTFDELRERNEKQLREILEEAAASEsdPGAVEKAKDLYKSCMDTDAIEKLGLKP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   175 LLSVLKMVGGWPVAMDKWnetmglkwELERQLAVLNSqFNRRVLIDLFIWNDDQNSSRHVIYIDQPTLGMPSREYYFQED 254
Cdd:pfam05649  81 LKPLLDEIGGPLANKDKF--------DLLETLAKLRR-YGVDSLFGFGVGPDDKNSSRNILYLDQPGLGLPDRDYYLKDR 151
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   255 NNH--KVRKAYLEFMTSVATMLRKDQNlskesamVREEMAEVLELETHLANATVPQEKRHDVTALYHRMDLMELQERFgl 332
Cdd:pfam05649 152 DEKsaEIREAYKAYIAKLLTLLGASEE-------AAALAEEVLAFETKLAKASLSREERRDPEKTYNPMTLAELQKLA-- 222
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   333 KGFNWTLFIQNVLssveVELFPDEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFKEARVDYRKAL 412
Cdd:pfam05649 223 PGIDWKAYLNAAG----LPDVPSDEVIVSQPEYLKALSKLLAETPLRTLKNYLIWRLVRSLAPYLSDEFRDANFEFYGTL 298
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   413 YGTTVEEvRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKKKAQEKAMNIRE 492
Cdd:pfam05649 299 SGTKQRP-RWKRCVSLVNGLLGEALGRLYVKKYFPEEAKARVEELVENIKEAFRERLDELDWMDEETKKKALEKLDAMTV 377

                  ....*
gi 10505362   493 QIGYP 497
Cdd:pfam05649 378 KIGYP 382
 
Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
96-763 0e+00

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 787.33  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362  96 NPCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQH--RPAVEKAKTLYRSCMNQSVIEKRDSE 173
Cdd:cd08662   2 DPCDDFYQYACGNWLKNHPIPADKSSWGSFSELQDRNEEQLREILEEAASSAadSSAEQKAKDFYKSCMDEEAIEKLGLK 81
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 174 PLLSVLKMVGGWPVAMDKWNETmglkwelerqLAVLNSQFNRRVLIDLFIWNDDQNSSRHVIYIDQPTLGMPSREYYFQE 253
Cdd:cd08662  82 PLKPLLDKIGGLPSLDDLAAEL----------LLALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYLDE 151
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 254 DNNhKVRKAYLEFMTSVATMLRKDQNLSKEsamvreEMAEVLELETHLANATVPQEKRHDVTALYHRMDLMELQERFglK 333
Cdd:cd08662 152 ENA-EIREAYKKYIAKLLELLGADEEEAEK------LAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLA--P 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 334 GFNWTLFIQNVLSSVEvelfPDEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFKEARVDYRKALY 413
Cdd:cd08662 223 SIDWKAYLKALGPPAD----DPDKVIVSQPEYLKKLDKLLASTPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFYGKALS 298
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 414 GTTVEEVRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKKKAQEKAMNIREQ 493
Cdd:cd08662 299 GQKEPEPRWKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLDAMKVK 378
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 494 IGYPDYILedNNKHLDEEYSSLTFyEDLYFENGLQNLKNNAQRSLKKLREKVDQNLWIIGAAVVNAFYSPNRNQIVFPAG 573
Cdd:cd08662 379 IGYPDKWR--DYSALDIYYDDLNV-SDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIVFPAG 455
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 574 ILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSARHFQQQSQCMIYQYGNFswELADNQN 653
Cdd:cd08662 456 ILQPPFFDPDAPDALNYGGIGAVIGHEITHGFDDQGRQYDENGNLRNWWTNEDRKEFEERAQCLVDQYSNY--EVPPGLH 533
                       570       580       590       600       610       620       630       640
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 654 VNGFSTLGENIADNGGVRQAYKAYLRWLADGGKDQrLPGLNLTYAQLFFINYAQVWCGSYRPEFAVQSIKTDVHSPLKYR 733
Cdd:cd08662 534 VNGKLTLGENIADNGGLRLAYRAYKKWLKENGPEL-PGLEGFTPEQLFFLSFAQVWCSKYRPEALRQLLLTDPHSPGKFR 612
                       650       660       670
                ....*....|....*....|....*....|
gi 10505362 734 VLGSLQNLPGFSEAFHCPRGSPMHPMKRCR 763
Cdd:cd08662 613 VNGPLSNSPEFAEAFNCPPGSPMNPEKKCR 642
PepO COG3590
Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];
88-765 0e+00

Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];


Pssm-ID: 442809 [Multi-domain]  Cd Length: 674  Bit Score: 620.63  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362  88 LENMDQSRNPCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQHRPA--VE-KAKTLYRSCMNQ 164
Cdd:COG3590  30 LANMDTSVRPGDDFYRYVNGGWLKTTPIPADRSRWGSFNELRERNEARLRAILEEAAAAPAAAgsDEqKIGDLYASFMDE 109
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 165 SVIEKRDSEPLLSVLKMVggwpvamdkwnETMGLKWELERQLAVLNSQFNRrVLIDLFIWNDDQNSSRHVIYIDQPTLGM 244
Cdd:COG3590 110 AAIEALGLAPLKPDLARI-----------DAIKDKADLAALLAALHRAGVG-GLFGFGVDADLKNSTRYIAYLGQGGLGL 177
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 245 PSREYYFQEDNNHK-VRKAYLEFmtsVATMLRkdqnLSKESAMVREEMAE-VLELETHLANATVPQEKRHDVTALYHRMD 322
Cdd:COG3590 178 PDRDYYLKDDEKSAeIRAAYVAH---VAKMLE----LAGYDEADAAAAAEaVLALETALAKAHWSRVELRDPEKTYNPMT 250
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 323 LMELQERFglKGFNWTLFiqnvLSSVEVELFpdEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFK 402
Cdd:COG3590 251 VAELAKLA--PGFDWDAY----LKALGLPAV--DEVIVGQPSFFKALDKLLASTPLEDWKAYLRWHLLDSAAPYLSKAFV 322
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 403 EARVD-YRKALYGTTVEEVRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKK 481
Cdd:COG3590 323 DANFDfYGKTLSGQKEQRPRWKRAVALVNGALGEALGQLYVERYFPPEAKARMEELVANLRAAYRERIENLDWMSPETKA 402
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 482 KAQEKAMNIREQIGYPDYilednnkhlDEEYSSLTFYEDLYFENGLQNLKNNAQRSLKKLREKVDQNLWIIGAAVVNAFY 561
Cdd:COG3590 403 KALEKLAAFTPKIGYPDK---------WRDYSGLEIKRDDLVGNVLRASAFEYQRELAKLGKPVDRTEWGMTPQTVNAYY 473
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 562 SPNRNQIVFPAGILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSARHFQQQSQCMIYQY 641
Cdd:COG3590 474 NPTMNEIVFPAAILQPPFFDPKADDAVNYGGIGAVIGHEITHGFDDQGSQFDGDGNLRNWWTPEDRAAFEARTKKLVAQY 553
                       570       580       590       600       610       620       630       640
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362 642 GNFswELADNQNVNGFSTLGENIADNGGVRQAYKAYLRWLadggKDQRLPGLN-LTYAQLFFINYAQVWCGSYRPEFAVQ 720
Cdd:COG3590 554 DAY--EPLPGLHVNGKLTLGENIADLGGLSIAYDAYKLSL----KGKEAPVIDgFTGDQRFFLGWAQVWRSKARDEALRQ 627
                       650       660       670       680
                ....*....|....*....|....*....|....*....|....*..
gi 10505362 721 SIKTDVHSPLKYRVLGSLQNLPGFSEAFHCPRGSPMH--PMKRCRIW 765
Cdd:COG3590 628 RLATDPHSPGEFRVNGPVRNLDAFYEAFDVKPGDKMYlaPEDRVRIW 674
Peptidase_M13_N pfam05649
Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of ...
97-497 4.32e-149

Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of organizms including mammals and bacteria. In mammals they participate in processes such as cardiovascular development, blood-pressure regulation, nervous control of respiration, and regulation of the function of neuropeptides in the central nervous system. In bacteria they may be used for digestion of milk.


Pssm-ID: 461703  Cd Length: 382  Bit Score: 440.58  E-value: 4.32e-149
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362    97 PCENFYQYACGGWLRHHVIPETNSRYSVFDILRDELEVILKGVLEDSTSQH--RPAVEKAKTLYRSCMNQSVIEKRDSEP 174
Cdd:pfam05649   1 PCDDFYQYACGGWLKNHPIPADKSSWGTFDELRERNEKQLREILEEAAASEsdPGAVEKAKDLYKSCMDTDAIEKLGLKP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   175 LLSVLKMVGGWPVAMDKWnetmglkwELERQLAVLNSqFNRRVLIDLFIWNDDQNSSRHVIYIDQPTLGMPSREYYFQED 254
Cdd:pfam05649  81 LKPLLDEIGGPLANKDKF--------DLLETLAKLRR-YGVDSLFGFGVGPDDKNSSRNILYLDQPGLGLPDRDYYLKDR 151
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   255 NNH--KVRKAYLEFMTSVATMLRKDQNlskesamVREEMAEVLELETHLANATVPQEKRHDVTALYHRMDLMELQERFgl 332
Cdd:pfam05649 152 DEKsaEIREAYKAYIAKLLTLLGASEE-------AAALAEEVLAFETKLAKASLSREERRDPEKTYNPMTLAELQKLA-- 222
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   333 KGFNWTLFIQNVLssveVELFPDEEVVVYGIPYLENLEDIIDSYSARTMQNYLVWRLVLDRIGSLSQRFKEARVDYRKAL 412
Cdd:pfam05649 223 PGIDWKAYLNAAG----LPDVPSDEVIVSQPEYLKALSKLLAETPLRTLKNYLIWRLVRSLAPYLSDEFRDANFEFYGTL 298
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   413 YGTTVEEvRWRECVSYVNSNMESAVGSLYIKRAFSKDSKSTVRELIEKIRSVFVDNLDELNWMDEESKKKAQEKAMNIRE 492
Cdd:pfam05649 299 SGTKQRP-RWKRCVSLVNGLLGEALGRLYVKKYFPEEAKARVEELVENIKEAFRERLDELDWMDEETKKKALEKLDAMTV 377

                  ....*
gi 10505362   493 QIGYP 497
Cdd:pfam05649 378 KIGYP 382
Peptidase_M13 pfam01431
Peptidase family M13; Mammalian enzymes are typically type-II membrane anchored enzymes which ...
558-764 1.83e-85

Peptidase family M13; Mammalian enzymes are typically type-II membrane anchored enzymes which are known, or believed to activate or inactivate oligopeptide (pro)-hormones such as opioid peptides. The family also contains a bacterial member believed to be involved with milk protein cleavage.


Pssm-ID: 279739 [Multi-domain]  Cd Length: 205  Bit Score: 269.28  E-value: 1.83e-85
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   558 NAFYSPNRNQIVFPAGILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSARHFQQQSQCM 637
Cdd:pfam01431   1 NAYYQPNRNEIVFPAAILQPPFFDPNYPRAVNYGGIGNVIAHEITHGFDDQGAQFDKDGNLRSWWTDEDAEEFKDRAQCL 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 10505362   638 IYQYGNFSwELADNQNVNGFSTLGENIADNGGVRQAYKAYLRwlADGGKDQRLPGL-NLTYAQLFFINYAQVWCGSYRPE 716
Cdd:pfam01431  81 IEQYSEYT-PPDGTKCANGTLTLGENIADLGGLTIALRAYKK--LLSANETVLPGFeNLTPDQLFFRGAAQIWCMKQSPA 157
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....*...
gi 10505362   717 FAVQSIKTDVHSPLKYRVLGSLQNLPGFSEAFHCPRGSPMHPMKRCRI 764
Cdd:pfam01431 158 EVLRQLLVDPHSPPEFRVNGVMSNMPAFYEAFNCPEGDKMNPEPRCRL 205
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
552-615 1.62e-06

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 47.09  E-value: 1.62e-06
                        10        20        30        40        50        60
                ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 10505362 552 IGAAVVNAFYSPNrNQIVFPAGILQppffskdqpqslNFGGIGMVIGHEITHGFDDNGRNFDKN 615
Cdd:cd09594  37 VEVNAYNAMWIPS-TNIFYGAGILD------------TLSGTIDVLAHELTHAFTGQFSNLMYS 87
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH